点击注册小程序 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客 户，用作新媒体形势下研究信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿 订阅、接收或使用本订阅号中的任何信息。本订阅号难以设置访问权限，若给您造成不便， 敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相关人员为光大 证券的客户。 报告摘要 事件： 2025年12月7日，国家医保局、人力资源社会保障部发布《国家基本医疗保险、工伤保险和生育保险药品 目录（2025年）》以及首版《商业健康保险创新药品目录（2025年）》，要求进一步推动商业健康保险与 基本医保的有效衔接。 点评： 基本医保谈判成功率创7年新高，首版商保目录纳入19种药品 本次调整后，医保目录内药品总数从3159种增加至3253种，其中西药1857种、中成药1396种，协议期内谈 判药品部分472种（含西药411种，中成药61种）。本次基本医保目录，共有127种目录外药品参与谈判， 其中112种谈判成功，成功率为88%，成功率创7年新高。新增药品主要治疗领域为肿瘤、抗感染、慢性病 和罕见病。首版商保目 ...

人民财讯12月6日电，据国家医保局消息，2025创新药高质量发展大会将于12月7日(本周日)9:00在广州 召开，会议将发布2025年《国家基本医疗保险、生育保险和工伤保险药品目录》和2025年《商业健康保 险创新药品目录》。 ...

"十五五"期间，我国将围绕人口结构变化、群众就医需求持续释放、科学技术发展等新情况持续推进全 民医疗保障制度改革。 《措施》提出，促进创新药全球市场发展。发挥我国巨大产能、超大市场和丰富经验的优势，在国际交 流合作中主动宣传推介中国创新药发展成果。鼓励引导有条件的地区探索面向东南亚、中亚和其他共 建"一带一路"国家搭建全球创新药交易平台，加强国际推广。支持创新药企业借助香港、澳门相关优 势，促进中国创新药走向世界。鼓励更多创新药进入中国市场，更好满足群众用药需求。 10月30日-11月3日，国家医保局组织开展2025年国家基本医保药品目录谈判竞价和商保创新药目录价格 协商工作，120家内外资企业现场参与，其中参与基本医保药品目录谈判竞价的目录外药品127个，参与 商保创新药目录价格协商的药品24个。 国家医保局日前发出预告，2025创新药高质量发展大会将于12月7日在广州召开，会议将发布2025年 《国家基本医疗保险、生育保险和工伤保险药品目录》和2025年《商业健康保险创新药品目录》。 章轲表示，"十四五"时期，每年数万亿元医保资金为医疗事业注入动力，既保障了患者就医，也成为医 疗机构发展的重要支撑，并以战 ...

Core Insights - The article highlights the role of the Xinchao Innovation Center in fostering innovation within the biopharmaceutical sector in Beijing, emphasizing its commitment to supporting original innovation and the exploration of the unknown [1][3][4]. Group 1: Company Overview - Xinchao Innovation Center has incubated 102 companies since its establishment in 2019, including projects from prestigious institutions like Tsinghua University and Harvard University [3]. - The center has facilitated the clinical trial phase for six globally innovative drugs and nurtured two unicorns and 25 national high-tech enterprises, with total financing exceeding 6.5 billion yuan [3]. - The center provides comprehensive support throughout the lifecycle of biopharmaceutical companies, aiming to lower barriers for scientists entering entrepreneurship [3][4]. Group 2: Industry Development - Beijing's biopharmaceutical industry is projected to exceed 1 trillion yuan in scale by 2024, with a reported value of 1.06 trillion yuan [6][5]. - The city has seen significant growth in its pharmaceutical sector, with 436 large-scale pharmaceutical enterprises generating approximately 185 billion yuan in output value [6]. - The "South-North Linkage" strategy is being implemented to enhance industrial upgrades, with the southern region focusing on the International Pharmaceutical Innovation Park and the northern region centered around the Zhongguancun Life Science Park [6][5]. Group 3: Policy and Support - Beijing has introduced a series of measures to promote high-quality development in the innovative pharmaceutical sector, including a reduction in clinical trial approval times from 60 days to 30 days [7][8]. - The new "32 measures" aim to support the pharmaceutical industry through various initiatives, such as expanding the training of project leaders and simplifying drug approval processes [8]. - A 10 billion yuan pharmaceutical merger fund has been established to further support the industry, alongside initiatives for talent acquisition and intellectual property protection [8].

Core Viewpoint - The article highlights the significant growth and transformation of China's innovative pharmaceutical industry, particularly focusing on Heng Rui Medicine's achievements and its role as a leader in this sector. The company has successfully transitioned from a follower to a leader in innovation, marking a new era of high-quality development in the industry [1][28]. Financial Performance - In the first half of 2025, Heng Rui Medicine achieved a revenue of 15.761 billion yuan, representing a year-on-year growth of 15.88% [3]. - The sales and licensing revenue from innovative drugs reached 9.561 billion yuan, accounting for 60.66% of total revenue, indicating a significant shift towards high-quality development [3]. - The net profit for the same period was 4.45 billion yuan, reflecting a year-on-year increase of 29.67%, with a net profit margin of 28.26%, marking a new high since the company's listing [5]. Research and Development - Heng Rui Medicine has maintained a high level of R&D investment, with over 6 billion yuan invested annually in the past three years, representing more than 25% of sales revenue [4]. - In the first half of 2025, R&D expenditure reached 3.871 billion yuan, supporting sustainable innovation [4]. - The company has a robust pipeline with 23 approved first-class innovative drugs and over 100 self-innovated products in clinical development [12]. Global Expansion - Heng Rui Medicine has initiated over 20 overseas clinical trials in various countries, including the US, Europe, and Japan, to promote its innovative drugs globally [16]. - The company has engaged in significant licensing agreements, including a partnership with GSK to develop up to 12 innovative drugs, with an upfront payment of 500 million USD and potential total payments of around 12 billion USD [17]. Industry Trends - The Chinese innovative pharmaceutical sector is experiencing a transformation from imitation to independent innovation, supported by favorable policies and market dynamics [19][20]. - The market for innovative drugs in China is projected to exceed 2 trillion yuan by 2030, with a compound annual growth rate of 24.1% from 2024 to 2030 [22]. - The pharmaceutical sector is viewed as a high-quality investment area, with the industry index showing a strong recovery and growth potential [25].

Group 1: Medical Insurance Development - The National Medical Insurance Bureau emphasizes the need to empower the pharmaceutical industry and implement measures to support high-quality development of innovative drugs [1][2] - By mid-2025, significant progress is expected in medical insurance, including an increase in the number of insured individuals under maternity insurance to 253 million, with expenditures reaching 67.832 billion yuan in the first half of the year [1] - The meeting highlighted the importance of direct settlement of medical expenses for drug procurement enterprises, with an average settlement cycle reduced to within 30 days [1][2] Group 2: Maternity Insurance and Long-term Care - The meeting encourages regions to include flexible employment workers, migrant workers, and new employment forms in maternity insurance coverage, while also exploring basic service packages for prenatal check-ups [3] - Long-term care insurance will be comprehensively implemented, with a focus on planning and supporting community-based care services [3] Group 3: Healthcare System Reform - The meeting calls for the reform of medical service pricing and the expansion of immediate settlement of medical insurance funds to healthcare institutions [2] - There is a push for the integration of technology in medical insurance, transitioning from passive payment to proactive empowerment and health investment [3]

Group 1 - The core point of the news is that China Europe Fund announced a limit on daily subscriptions for the China Europe Medical Innovation Fund to 100,000 yuan starting from August 11, 2025, to ensure stable fund operations and protect the interests of fund shareholders [1][2][3] - The China Europe Medical Innovation Fund, managed by fund manager Ge Lan, was established in February 2019 and primarily invests in stocks related to medical innovation [3][4] - As of mid-2023, the fund's total net asset value exceeded 8.2 billion yuan, with major investments in healthcare and manufacturing sectors, accounting for 46.41% and 41.99% of the total assets, respectively [5][6] Group 2 - The top ten holdings of the fund include companies such as Sanofi Pharmaceutical, Keren Biotechnology, and Kangfang Biotech, with the largest holding, Sanofi Pharmaceutical, showing a year-to-date increase of nearly 400% [4][6] - The fund's unit net value has been rising, reaching 1.6874 yuan, compared to a low of below 0.9 yuan a year ago [7][8] - The fund's outlook for the third quarter highlights optimism in the innovative drug sector, with expectations for global collaboration and important clinical data disclosures, as well as ongoing domestic policy support for high-quality drug development [8]

Investment Rating - The report maintains a "Recommended" investment rating for the healthcare sector [7]. Core Viewpoints - The report highlights a positive outlook on innovative drugs and emphasizes the importance of the upstream supply chain [5][22]. - The recent measures introduced by the National Healthcare Security Administration and the National Health Commission aim to support the high-quality development of innovative drugs, which includes increasing support for R&D and enhancing the role of commercial insurance in the multi-tiered medical security system [4][21]. Summary by Sections 1. Market Performance Review - From July 7 to July 11, 2025, the Shenwan Pharmaceutical and Biological Index increased by 1.82%, outperforming the CSI 300 Index by 1.00 percentage points, ranking 16th among 31 Shenwan first-level industry indices [2][12]. - Year-to-date, the Shenwan Pharmaceutical and Biological Index has risen by 12.11%, surpassing the CSI 300 Index by 10.08 percentage points, ranking 4th among the 31 indices [14][17]. 2. Important Events - The recent introduction of 16 measures to support the high-quality development of innovative drugs includes enhancing R&D support, facilitating access to basic medical insurance and commercial health insurance, and improving payment capabilities for innovative drugs [4][21]. 3. Industry Insights - The report emphasizes the growing role of commercial insurance in the multi-tiered medical security system, which is expected to provide greater flexibility and support for high-priced innovative drugs and medical devices [5][22]. - The innovative drug sector is entering a phase of realization of results, with significant R&D progress expected to drive investment in 2025 [22]. - The report suggests focusing on companies involved in overseas expansion, particularly in emerging markets, as they present substantial growth potential [22]. - The ongoing acceleration of centralized procurement in various pharmaceutical sectors is anticipated to lead to new growth opportunities, particularly in insulin and orthopedic segments [22].

Report Summary 1. Industry Investment Rating No industry investment rating is provided in the report. 2. Core Views - The market interprets the "anti - involution" policy as a price rebound rather than a reversal. Stocks in coal, transportation, and steel industries led the decline, while those in electronics, power equipment, and pharmaceutical biology industries led the rise. The semi - annual report pre - increase theme is a visible investment line until mid - July. In the high - level oscillation period, it is advisable to focus on arbitrage opportunities by going long on far - month contracts and short on near - month contracts in the stock index futures market [1][6]. - In the stock index options market, due to low trading liquidity and volatility, and the potential ineffectiveness of sentiment indicators, it is recommended to adopt a covered defense strategy [2][6]. - In the treasury bond futures market, the short - end performed better than the long - end. The long - end bullish sentiment weakened marginally. In the short term, the bond market is expected to continue to oscillate due to factors such as the central bank's cautious liquidity injection, high local bond supply in July, and potential tariff disturbances [2][7][8]. 3. Summary by Directory 3.1 Market Views - **Stock Index Futures** - **Data**: IF, IH, IC, IM's current - month basis points were - 21.47, - 16.95, - 48.66, - 63.24 respectively, with changes of 1.22, 2.6, - 12.31, - 15.95 points compared to the previous trading day; the current - month to next - month spreads were 18.6, 4.6, 54.2, 71.8 points respectively, with changes of 0.8, - 0.8, 3.8, - 1.6 points; the positions changed by - 481, - 1877, 1566, 2566 lots respectively [6]. - **Logic**: The market interprets the "anti - involution" policy as a price rebound. After excluding inflation - chain investment opportunities, funds rotate among scattered hot industries. There is a lack of a main line to boost trading volume during the high - level oscillation period [6]. - **Operation Suggestion**: Hold a wait - and - see attitude [6]. - **Stock Index Options** - **Data**: The trading volume of the options market rebounded slightly, but the overall trading liquidity remained low. The implied volatility of CSI 1000 index options dropped by 0.39%, and that of SSE 500 ETF options decreased by 0.18% [2][6]. - **Logic**: The double - low situation of liquidity and volatility, combined with the ineffective sentiment indicators, indicates that the index has resistance above and the market will continue to oscillate [2][6]. - **Operation Suggestion**: Adopt a covered defense strategy [2][6]. - **Treasury Bond Futures** - **Data**: The trading volumes of T, TF, TS, TL's current - quarter contracts were 64924, 51486, 24843, 72609 lots respectively, with 1 - day changes of 6969, 5555, - 101, 3741 lots; the positions were 206020, 156476, 115715, 117980 lots respectively, with 1 - day changes of - 499, - 1347, 120, - 1737 lots. Other spread and basis data are also provided [7]. - **Logic**: The long - end bullish sentiment weakened marginally due to the stock - bond seesaw effect and the profit - taking motivation of long - end futures. The central bank may be cautious in liquidity injection, and the local bond supply in July may be high, limiting the downward space of interest rates. Tariff disturbances may increase after July 9 [2][7][8]. - **Operation Suggestion**: Maintain an oscillating trend strategy; pay attention to short - hedging at low basis levels; appropriately focus on basis widening; the mid - term strategy of steepening the yield curve has higher odds [8]. 3.2 Economic Calendar - The official manufacturing PMI in China in June was 49.7, up from 49.5 in the previous month. The final value of the US Markit manufacturing PMI in June was 52.9, higher than the expected and previous values. The US unemployment rate in June was 4.1%, lower than the expected 4.3% and the previous 4.2%, and the non - farm payrolls increased by 14.7 million, higher than the expected 10.6 million [9]. 3.3 Important Information and News Tracking - **Domestic Macro**: On July 3, the Minister of the Ministry of Industry and Information Technology hosted a manufacturing enterprise symposium, where 14 photovoltaic enterprises and industry association representatives exchanged views on various aspects and put forward policy suggestions [9]. - **Overseas Macro**: The US non - farm payrolls increased by 14.7 million in June, higher than expected, and the unemployment rate dropped to 4.1%. The private - sector employment increased by only 7.4 million, the lowest since last October, mainly driven by the healthcare industry [10]. 3.4 Derivatives Market Monitoring - The report mentions the monitoring of stock index futures, stock index options, and treasury bond futures data, but specific data details are not fully presented in the provided content [11][15][27].

Group 1 - Barclays Bank is the largest holder of the newly listed Hong Kong innovative drug ETF, holding 20 million shares, which accounts for 4.5997% of the total fund shares [2][3] - The innovative drug sector has seen a significant rebound since the end of 2024, with the Hang Seng Innovative Drug Index rising nearly 68% year-to-date as of July 2 [7] - The recent policy measures from the National Healthcare Security Administration and the National Health Commission aim to support the high-quality development of innovative drugs, proposing 16 measures to enhance R&D support and improve market accessibility [7][8] Group 2 - In the past, Barclays also held a significant position in the Huatai-PineBridge Hang Seng Innovative Drug ETF, owning 85 million shares, which represented 42.02% of the total shares, with a return of over 56% since its inception [4][2] - Recent trends show that the top holders of other innovative drug ETFs are primarily brokerages, private equity, individual investors, and corporate pension plans, indicating a diverse investor base [5] - The innovative drug industry in China is at a critical turning point, with a focus on ADC and dual-antibody technologies, which are expected to capture significant market share in global immunotherapy [8]